QSI — Quantum-Si incorporated

QSI (Quantum-Si) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $451,000, impacted by capital sales headwinds.
• Full Year Revenue: $2.4 million, with a gross profit of $1.2 million and a gross margin of 47%.
• Q4 Gross Profit: $122,000, resulting in a gross margin of 27%, affected by revenue mix and inventory adjustments.
• Operating Expenses: Q4 GAAP operating expenses were $21.2 million, down from $31.3 million in Q4 2024. Full year GAAP operating expenses totaled $117.3 million, slightly up from $110.2 million in 2024.
• Cash Position: As of December 31, 2025, QSI had $215.8 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Corporate Priorities: Focus on accelerating commercial adoption, delivering innovation, and preserving financial strength.
• Consumable Revenue: Anticipated growth in consumable utilization from the installed base, with a projected 25% increase in consumable kits run by customers in 2026.
• Proteus Development: Significant focus on the upcoming launch of the Proteus system, expected at the end of 2026. The list price for Proteus was announced at $425,000.
• Customer Engagement: Secured 17 new customers through an expanded instrument acquisition program, enhancing access to key opinion leaders and building a publication pipeline.
• Innovation: Successful launches of new sequencing kits and library prep kits, with ongoing improvements in proteome coverage and sequencing capabilities.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be approximately $1 million, primarily from consumables and services.
• Operating Expenses: Anticipated adjusted operating expenses of $98 million or less, with total cash usage projected at $93 million or less.
• Transition Year: 2026 is viewed as a transition year focusing on preparing for the Proteus launch rather than maximizing near-term revenue.

4. Bad News, Challenges, or Points of Concern

• Capital Sales Headwinds: Continued challenges in capital sales due to uncertainties in NIH funding and budget constraints affecting customer capital expenditure decisions.
• Limited New Capital Sales: Expectation of very modest new placements for the Platinum Pro instrument as customers delay purchases in anticipation of the Proteus launch.
• Gross Margin Pressure: Anticipated lower gross margins in 2026 due to a higher proportion of consumable sales and potential deferred revenue recognition from credits offered for future Proteus purchases.

5. Notable Q&A Insights

• Consumable Trends: Customers are purchasing consumables at a consistent rate, with expectations for increased utilization as the market prepares for Proteus.
• Customer Feedback: Many customers prefer to wait for Proteus before making new capital purchases, indicating a strategic shift in focus.
• Sales Strategy: QSI is considering various acquisition models for Proteus but will initially launch with direct capital sales only.
• Technical Risks: While technical innovation has been achieved, risks remain in hardware integration and performance optimization leading up to the launch.
• Market Conditions: The company is monitoring NIH funding dynamics but has not received specific concerns from customers regarding capital budgets.

This summary encapsulates the key points from the earnings call, reflecting both the current state and future outlook of Quantum-Si as they navigate a pivotal year ahead.